• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

SGLT2 Inhibitors & GLP-1 Receptor Agonists: Differences, Similarities, Patient Selection

Slideshow

SGLT2 inhibitors and GLP-1 receptor agonists are changing the type 2 diabetes treatment paradigm. We summarize the most recent data here and offer guidance on patient benefits.

Newer classes of diabetes drugs have brought a paradigm shift in diabetes management. Several large cardiovascular outcome trials suggest that SGLT2 inhibitors and GLP1 receptor agonists both decrease cardiovascular risk, and some studies suggest a role for renoprotection.

Recent research raises several important questions: Is there a difference between SGLT2 inhibitors and GLP1 agonists for cardiovascular and renal protection? If so, which one is better, and for which patients? Evidence and guidance follow.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
© 2024 MJH Life Sciences

All rights reserved.